Literature review on the immunogenicity of herpes zoster vaccines .: HP40-243/2018E-PDF
"Herpes zoster is an acute viral infection caused by reactivation of varicella-zoster virus (VZV). LZV, a live, attenuated vaccine for zoster has been available in Canada for many years. A new subunit recombinant zoster vaccine (RZV) named Shingrix was approved in Canada in October 2017. This zoster vaccine immunogenicity review was done to have a comprehensive understanding of the immunogenicity of both live and subunit vaccines"--Executive summary, p. 3.
Permanent link to this Catalogue record:
|Department/Agency||Canada. Public Health Agency of Canada.|
|Title||Literature review on the immunogenicity of herpes zoster vaccines .|
|Other language editions||[French]|
|Note(s)|| Issued also in French under title: Revue de la littérature sur l'immunogénicité des vaccins contre le zona. |
"Publication date: January 2019."
"An Advisory Committee Review (ACR), National Advisory Committee on Immunization (NACI)."
Includes bibliographical references.
|Publishing information||[Ottawa] : Public Health Agency of Canada, 2019.|
|Catalogue number|| |
|Departmental catalogue number||Pub. : 180582|
Request alternate formatsTo request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.
- Date modified: